GSTP SSRIs: Trintellix
Defines initial step therapy and prior authorization criteria for the branded antidepressant Trintellix under CVS/Caremark-administered prescription benefit for Neighborhood Health Plan of Rhode Island members; includes coverage criteria, duration of approval, and initial claim reject behavior when step therapy not met.
No material clinical/coverage changes.
Coverage Summary
Coverage stance: covered_with_criteria. Scope: Defines initial step therapy and prior authorization criteria for the branded antidepressant Trintellix under a CVS/Caremark-administered prescription benefit for Neighborhood Health Plan of Rhode Island members; the CVS/Caremark-derived policy requires a generic-first step therapy (trial, intolerance, or contraindication to at least one generic SSRI or generic SSRI combination product) before branded Trintellix will be paid. Duration of Approval (DOA): 24 months. High-level claim behavior: if the step therapy requirement is not met, the claim will reject and a prior authorization (PA) is required.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.